awmsg logo



beclometasone dipropionate/formoterol fumarate (Fostair®)


Reference No. 2364

Publication date:
30/06/2015


Appraisal information

beclometasone dipropionate/formoterol fumarate (Fostair®) 100 micrograms/6 micrograms inhalation solution


Company: Chiesi Ltd
BNF category: Respiratory system
NMG meeting date: 15/04/2015
AWMSG meeting date: 20/05/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1115
Ministerial ratification: 26/06/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Beclometasone dipropionate/formoterol fumarate (Fostair®) is recommended as an option for use within NHS Wales for the symptomatic treatment of patients with chronic obstructive pulmonary disease, with a FEV1 < 50% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download